EUDA Health Holdings Limited announced that its wholly‑owned subsidiary, EUDA Health Pte. Ltd., has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. The deal, disclosed on January 13 2026, provides up to RMB 6 million (US$930,000) in staged financing to upgrade Shenzhen Inno’s cGMP facility into a state‑of‑the‑art production and innovation center for stem‑cell therapies.
The loan is structured as a convertible note with a 6 % annual interest rate, payable semi‑annually. EUDA will receive an initial tranche of RMB 1 million, followed by a second tranche of RMB 5 million once due diligence, regulatory approvals and definitive agreements are completed. The note includes an option for EUDA to convert the debt into equity in Shenzhen Inno, with the conversion price to be determined at the time of conversion, potentially giving EUDA a significant ownership stake in the Chinese partner.
Shenzhen Inno, a developer of autologous cellular therapeutics, operates a stem‑cell technology platform that supports natural killer cells, gamma‑delta T cells, mesenchymal stem cells, induced pluripotent stem cells and organoids. The facility upgrade will expand capacity for cell processing, quality control and precision biological workflows, positioning the plant as a core technology hub for EUDA’s China strategy and accelerating the commercialization of EUDA’s longevity‑focused therapies.
EUDA’s CEO, Alfred Lim, emphasized that the phased, flexible investment structure allows the company to validate execution and align strategies before committing to a larger equity stake. Lim noted that the upgrade “reflects our disciplined approach to building long‑term stem‑cell therapy platforms. By supporting the upgrade and expansion of a high‑quality platform using a phased and flexible investment structure, we can validate execution, align our strategies, and create the foundation for deeper ownership and integration over time.” The deal comes amid EUDA’s broader push to launch a nationwide stem‑cell extraction, cryogenic storage and clinical delivery platform in China, and to integrate its QB utility token into its digital health ecosystem.
The convertible loan strengthens EUDA’s position in China’s rapidly growing regenerative‑medicine market while preserving liquidity. If the conversion option is exercised, EUDA could acquire a meaningful equity stake in a partner that has already attracted investment from HSG Capital Group (formerly Sequoia Capital China). The transaction also signals EUDA’s confidence in Shenzhen Inno’s technology and the broader stem‑cell market, despite recent reports of financial challenges within EUDA’s own balance sheet. The deal therefore represents a strategic bet on the long‑term growth of the longevity sector and a step toward deeper integration with a leading Chinese biotech partner.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.